Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Anaemia
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Anaemia
    TopAbstracts in Anaemia 09/03/2008 - (DGNews)
    TopAbstracts in Anaemia 08/20/2008 - (DGNews)
    New Test Measures Hepcidin, Can Help Diagnose Anaemias and Iron Disorders - (DGNews)
    TopAbstracts in Anaemia 08/07/2008 - (DGNews)
    Single Lot of Epoetin Alfa Recalled Due to Damaged Vials - (DGNews)

    News archive

     Recent webcasts/CME - Anaemia
    Bridging Interdisciplinary and Resource Gaps in CKD-Anemia Management

    Webcasts/CME archive

     Recent cases - Anaemia
      Severe Hemolytic Anemia as the First Manifestation of G6PD Deficiency in a Child with Acute Hepatitis A Infection
      Rare Ileal Localisation of Angiolipoma Presenting as Chronic Haemorrhage and Severe Anaemia: A Case Report
      Severe Thrombocytosis and Anemia Associated with Celiac Disease in a Young Female Patient: A Case Report
      Paroxysmal Cold Haemoglobinuria Leading to Acute Renal Failure: A Case Report
      Pancytopenia Due to Iron Deficiency Worsened by Iron Infusion: A Case Report

      Cases archive
        




      my personal edition > anaemia > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Investigative Drug Aranesp (Darbepoetin) Effective for Chemotherapy-Induced Anemia: Presented at ASH

      By Bruce Sylvester

      ATLANTA, GA -- December 14, 2005 -- Treatment of chemotherapy-induced anemia with the investigative agent darbepoetin (Aranesp) administered every 3 weeks is well tolerated and effective, according to phase 3 data presented here at the 47th Annual Meeting of the American Society of Hematology (ASH).

      "For the majority of patients in our study, we got them into a desirable hemoglobin range," said lead investigator Kerry Taylor, MD, hematologist, Mater Hospital, Brisbane, Australia, in his presentation on December 12th. "They feel better, and it was an easy schedule, which is adaptable to most chemotherapy regimens."

      Dr. Taylor and coinvestigators enrolled subjects who were 18 years older and had hemoglobin (Hb) levels lower than 11 g/ dL and a nonmyeloid malignancy with 12 weeks or more of planned chemotherapy.

      Subjects were randomized in a 1:1 ratio; 193 received darbepoetin 300 mcg and 193 received placebo every 3 weeks for 15 weeks.

      The investigators assessed treatment efficacy by measuring incidence of red blood cell (RBC) transfusions and achievement of a target Hb level of 11 g/dL or higher (not exceeding 13 g/dL).

      They treated 386 subjects for up to 16 weeks.

      Results show that 77% of the darbepoetin group achieved the target hemoglobin level compared with 55% in the placebo group.

      From week 5 to the end of treatment, the incidence of red blood cell transfusions was significantly lower in the darbepoetin group (24%) than in the placebo group (41%).

      "In addition, there was very little toxicity." Dr. Taylor noted.

      The study was supported by Amgen.


      [Presentation title: Randomized, Double-Blind, Placebo-Controlled Study of Darbepoetin alfa Every 3 Weeks for the Treatment of Chemotherapy-Induced Anemia. Abstract 3556]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send